We are live on
!
Find out more
SNNA
Sienna Biopharmaceuticals, Inc.
SNNA
SNNA
Delisted
SNNA was delisted on the 16th of December, 2019.
60 hedge funds and large institutions have $21.6M invested in Sienna Biopharmaceuticals, Inc. in 2018 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 15 increasing their positions, 19 reducing their positions, and 6 closing their positions.
New
Increased
Maintained
Reduced
Closed
100% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 6
11% more funds holding
Funds holding: 54 → 60 (+6)
21% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 19
86% less capital invested
Capital invested by funds: $151M → $21.6M (-$129M)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Holders
60
Holders Change
+6
Holders Change %
+11.11%
% of All Funds
1.34%
Holding in Top 10
–
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-100%
% of All Funds
–
New
12
Increased
15
Reduced
19
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
Morgan Stanley
New York
|
+$1.36M |
| 2 |
Renaissance Technologies
New York
|
+$1.05M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$591K |
| 4 |
Two Sigma Investments
New York
|
+$565K |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$450K |
Top Sellers
| 1 |
Victory Capital Management
San Antonio,
Texas
|
-$7.55M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$3.79M |
| 3 |
BlackRock
New York
|
-$2.21M |
| 4 |
CCP
Clough Capital Partners
Boston,
Massachusetts
|
-$944K |
| 5 |
TAM
Tiverton Asset Management
Wilimington,
Delaware
|
-$594K |
